The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity
Open accessAbstract
SUMMARY Repair of damaged DNA is essential for maintaining genome integrity and for preventing genome-instability-associated diseases, such as cancer. By combining proximity labeling with quantitative mass spectrometry, we generated high-resolution interaction neighborhood maps of the endogenously expressed DNA repair factors 53BP1, BRCA1, and MDC1. Our spatially resolved interaction maps reveal rich network intricacies, identify shared and bait-spe-cific interaction modules, and implicate previously concealed regulators in this process. We identified a novel vertebrate-specific protein complex, shieldin, comprising REV7 plus three previously unchar-acterized proteins, RINN1 (CTC-534A2.2), RINN2 (FAM35A), and RINN3 (C20ORF196). Recruitment of shieldin to DSBs, via the ATM-RNF8-RNF168–53BP1-RIF1 axis, promotes NHEJ-dependent repair of intrachromosomal breaks, immunoglobulin class-switch recombination (CSR), and fusion of unpro-tected telomeres. Shieldin functions as a downstream effector of 53BP1-RIF1 in restraining DNA end resec-tion and in sensitizing BRCA1-deficient cells to PARP inhibitors. These findings have implications for under-standing cancer-associated PARPi resistance and the evolution of antibody CSR in higher vertebrates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464 · cited 1×
“…(2.2.1) Wickham, 2009 https://cran.r-project.org/web/ packages/ggplot2/ggplot2.pdf metafor (0.5-4) Viechtbauer, 2010 https://cran.r-project.org/web/ packages/metafor/metafor.pdf msa(1.10.0) Bodenhofer et al., 2015…”
InfluentialMultiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
UniProt: the Universal Protein knowledgebase
Apweiler, R. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh131 · Cited by 7,498
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment
Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., & Mann, M. (2011) · Journal of Proteome Research · doi:10.1021/pr101065j · Cited by 5,500
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Letunic, I., & Bork, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw290 · Cited by 5,016
Cited by
DNA double-strand break repair-pathway choice in somatic mammalian cells
Scully, R., Panday, A., Elango, R., & Willis, N. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0152-0 · Cited by 1,457
The Structure and Function of DNA G-Quadruplexes
Spiegel, J., Adhikari, S., & Balasubramanian, S. (2020) · Trends in Chemistry · doi:10.1016/j.trechm.2019.07.002 · Cited by 920
“Approaches that can reveal the composition and dynamics of chromatin-associated protein complexes [87,88] will be needed to uncover details of the proteins that”
BackgroundTargeting DNA damage response pathways in cancer
Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 836
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Atlas of Subcellular RNA Localization Revealed by APEX-Seq
Fazal, F. M., Han, S., Parker, K. R., Kaewsapsak, P., Xu, J., Boettiger, A. N., Chang, H. Y., & Ting, A. Y. (2019) · Cell · doi:10.1016/j.cell.2019.05.027 · Cited by 652
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Li, H., Liu, Z.-Y., Wu, N., Chen, Y.-C., Cheng, Q., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01227-0 · Cited by 539
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
Mechanisms of PARP inhibitor sensitivity and resistance
D’Andrea, A. D. (2018) · DNA Repair · doi:10.1016/j.dnarep.2018.08.021 · Cited by 489
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Noordermeer, S. M., & van Attikum, H. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.07.008 · Cited by 456
Phase separation of 53 BP 1 determines liquid‐like behavior of DNA repair compartments
Kilic, S., Lezaja, A., Gatti, M., Bianco, E., Michelena, J., Imhof, R., & Altmeyer, M. (2019) · The EMBO Journal · doi:10.15252/embj.2018101379 · Cited by 444
DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing
Xue, C., & Greene, E. C. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.02.008 · Cited by 431
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Dev, H., Chiang, T.-W. W., Lescale, C., de Krijger, I., Martin, A. G., Pilger, D., Coates, J., Sczaniecka-Clift, M., Wei, W., Ostermaier, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0140-1 · Cited by 417
Advances in genome editing through control of DNA repair pathways
Yeh, C. D., Richardson, C. D., & Corn, J. E. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0425-z · Cited by 405
The molecular basis and disease relevance of non-homologous DNA end joining
Zhao, B., Rothenberg, E., Ramsden, D. A., & Lieber, M. R. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00297-8 · Cited by 384
The Fanconi Anemia Pathway in Cancer
Niraj, J., Färkkilä, A., & D'Andrea, A. D. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050422 · Cited by 376
The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication
Tarsounas, M., & Sung, P. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0218-z · Cited by 359
DNA End Resection: Mechanism and Control
Cejka, P., & Symington, L. S. (2021) · Annual Review of Genetics · doi:10.1146/annurev-genet-071719-020312 · Cited by 293
Drug resistance in ovarian cancer: from mechanism to clinical trial
Wang, L., Wang, X., Zhu, X., Zhong, L., Jiang, Q., Wang, Y., Tang, Q., Li, Q., Zhang, C., Wang, H., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01967-3 · Cited by 255
The end protection problem—an unexpected twist in the tail
Ruis, P., & Boulton, S. J. (2021) · Genes & Development · doi:10.1101/gad.344044.120 · Cited by 57
Targeting DNA damage repair pathways in pancreas cancer
Crowley, F., Park, W., & O’Reilly, E. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09983-1 · Cited by 43
RIF1 acts in DNA repair through phosphopeptide recognition of 53BP1
Setiaputra, D., Escribano-Díaz, C., Reinert, J. K., Sadana, P., Zong, D., Callen, E., Sifri, C., Seebacher, J., Nussenzweig, A., Thomä, N. H., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.01.025 · Cited by 43
Self-citationPARP inhibitors for prostate cancer
Longoria, O., Beije, N., & de Bono, J. S. (2024) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.09.003 · Cited by 34
CHAMP1 complex directs heterochromatin assembly and promotes homology-directed DNA repair
Li, F., Zhang, T., Syed, A., Elbakry, A., Holmer, N., Nguyen, H., Mukkavalli, S., Greenberg, R. A., & D’Andrea, A. D. (2025) · Nature Communications · doi:10.1038/s41467-025-56834-6 · Cited by 13
Bedir, M., Outwin, E., Colnaghi, R., Bassett, L., Abramowicz, I., & O’Driscoll, M. (2024) · EMBO Reports · doi:10.1038/s44319-024-00184-9 · Cited by 6
Metadata
- Authors
- Gupta, R., Somyajit, K., Narita, T., Maskey, E., Stanlie, A., Kremer, M., Typas, D., Lammers, M., Mailand, N., Nussenzweig, A., Lukas, J., & Choudhary, C.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 173
- Issue
- 4
- Pages
- 972-988.e23
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2798183676
- Cited by
- 469
- References
- 60
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.